ISRCTN64760291已完成不适用
Pharmacokinetics of topical (0.25% solution bid) and oral (1 mg od) finasteride after single and 7 days multiple dose in male volunteers with androgeneic alopecia
Polichem S.A. (Switzerland)0 个研究点目标入组 24 人开始时间: 2013年8月8日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Sex: male
- •2. Age: 18-65 year-old inclusive
- •3. Androgeneic alopecia: recession of the frontal hairline and hair loss in the vertex or crown or loss of hair over the frontal and vertex scalp regions, corresponding to at least stage 2 of the Hamilton-Norwood scale
- •4. Body Mass Index (BMI): 18 < BMI < 30 kg/m2;
- •5. Vital signs: Systolic Blood Pressure (SBP) 100-139 mmHg, Diastolic Blood Pressure (DBP) 50-89 mmHg, Heart Rate (HR) 50-90 bpm, measured after 5 min of rest in the sitting position
- •6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study
- •7. Informed Consent: signed written informed consent prior to inclusion in the study
排除标准
- •1. Electrocardiogram (ECG) (12-leads) (supine position): clinically relevant abnormalities
- •2. Physical findings: clinically relevant abnormal physical findings which could interfere with the objectives of the study; in particular, skin damage such as abrasion, hyperkeratosis or any abnormal findings in the scalp
- •3. Laboratory analyses: clinically relevant abnormal laboratory values indicative of physical illness
- •4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
- •5. Diseases: relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases, that may interfere with the aim of the study
- •6. Medications: medications, including over the counter (OTC) drugs, for 2 weeks before the start of the study
- •7. Investigative drug trials: participation in the evaluation of any drug for 3 months before this study, calculated from the first day of the month following the last visit of the previous study
- •8. Blood donation: blood donations for 3 months before this study
- •9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>2 drinks/day], caffeine (>5 cups coffee/tea/day) or tobacco abuse (>10 cigarettes/day)
- •10. Abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study
研究者
相似试验
进行中（未招募）
1 期
An open label pharmcokinetic study of a topical formulation of lidocaine (SHACT) for pain relief in women receiving an Intra Uterine Device.EUCTR2011-005660-18-SEPharmanest AB15
进行中（未招募）
不适用
Pharmacokinetics and Pharmacodynamics of subcutaneous applied insulin aspart administered with the FlexPen® insulin pen compared to inhaled insulinadministered with the Exubera® deviceEUCTR2007-002060-10-DEikfe GmbH
已完成
不适用
Dermato-pharmacokinetic study of single application of lanoconazolehealthy volunteerJPRN-UMIN000029240Oita University6
已完成
1 期
Investigation of the efficacy of a herbal topical gel in reducing the skin reactions in cancer patients taking chemotherapy drugsHand and Foot Syndrome.Localized skin eruption due to drugs and medicamentsIRCT2015042116518N2Pharmaceutical Sciences branch, Islamic Azad University(a part of Elnaz Karimi's PharmD thesis)40
已完成
1 期
Investigation of the efficacy of a herbal topical gel in reducing the skin reactions in cancer patients taking chemotherapy drugs Fluoropyrimidines induced Hand-Foot Syndrome in cancerous patientshand-foot syndrome.localized skin eruption due to drugs and medicamentsIRCT2014051017643N1Pharmaceutical Sciences branch, Islamic Azad University(a part of razieh mohajerani's PharmD thesis40